U.S. Food and Drug Administration Approves BioMarin ' s Voxzogo (vosoritide) for Children Under 5 Years with Achondroplasia

SAN RAFAEL, Calif., Oct. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the U.S. Food and Drug Administration (FDA)...

Source: Drugs.com - New Drug Approvals - October 20, 2023 Category: Drugs & Pharmacology Source Type: news